The trial tests two oral forms of tafamidis, a key Pfizer drug for transthyretin amyloidosis (ATTR-PN). One is the existing 61 mg free acid capsule and the other is a new 61 mg free acid tablet, both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results